Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Interim Results

27th Mar 2007 07:02

International Medical Devices PLC27 March 2007 INTERNATIONAL MEDICAL DEVICES PLC INTERIM REPORT AND UNAUDITED RESULTS FOR THE SIX MONTHS ENDED 28 FEBRUARY 2007 MAIDEN PROFIT International Medical Devices PLC ("IMD") the medical supply company targetingthe medical consumables, cardiorespiratory, acute and aged care marketsannounces interim results for the six months ended 28 February 2007. Financial Highlights: 6 months 6 months end Feb '07 end Feb '06 £'000 £'000Profit and lossRevenue 5,063 779Operating profit/(loss) 416 (159)Profit/(loss) before tax 302 (158) Operational Highlights: • ClipOn safe needle received CE Marking for sales and distribution in Europe • Completed two acquisitions: ProCare Limited and Minster Medical Limited • Refinanced IMD through Allied Irish Banks plc • Exclusive distribution agreement signed with Inogen Inc., a leading supplier of oxygen concentrators Regarding Outlook, Lindsay Sanford, Chairman said: "IMD continues to deliver onits stated objectives. Our buy and build strategy is delivering a profitable,cash generative, medical device distribution business. Raised capital has beenused to finance acquisitions that have expanded our product portfolio andestablished channels to market in the UK and overseas that we will now begin toexploit by commercialising the safe needle technology acquired in 2005." For further information: International Medical Devices Corporate Synergy Parkgreen CommunicationsChris Thomas, CEO Mike Coe Victoria Thomas+44 203 008 4960 +44 117 933 0020 +44 207 851 7480 CHAIRMAN'S STATEMENT I am pleased to announce that in the last six months International MedicalDevices Plc (IMD) achieved sales of £5,063,000 and has delivered a profit beforetax of £302,000 after net interest payments of £114,000. This performance isproof that IMD is confirming its status within the UK healthcare sector as agrowing and profitable medical devices trading house. The Group's strategy continues to be 'build and buy', whilst at the same timefocusing on delivering organic growth in revenues and profits from the diverserange of technically innovative medical devices that constitute our product andbrand portfolio. Acquisitions/Acute Care Division In the period from September 2006 to end of February 2007, IMD made two furtheracquisitions that reinforce our Acute Care division. On completion, IMD paid £4million for Pro-Care Ltd and a further £760,000 for its sister company, MinsterMedical Ltd, before associated costs. These two acquisitions were funded throughthe provision of a term loan of £3.95 million through Allied Irish Bank Plc anda flexible book debt facility of up to £4 million, which allowed us to refinanceall existing group debt. The acquisition of Pro-Care Ltd and Minster Medical Ltd bring a broader,profitable product portfolio to IMD that includes enteral feeding tubing,specialist suction catheters, pain management delivery systems, cryo-surgerydevices, and neonatal and paediatric catheters. Both Meddis and Minster Medicalhave been successfully integrated into the Acute Care division which is headedby Pro-Care. The division has been divided into two separate units, EnteralFeeding and Suction Catheters, and trading has been strong in January andFebruary, since acquisition. Medical Consumables Division Through Response Medical, the Company has identified a growth opportunity in themedical consumables market that is linked to sales of capital equipment such asECG's and other monitoring devices. Response Medical sells such equipment and isnow focusing on its own label consumables catalogue that includes electrodes,cables, blood pressure cuffs, SPO2 sensors, defibrillator pads and ECG paper. Inaddition, sales of the Ypsomed penfine diabetic needle continue to increase inan expanding market. Cardiorespiratory division Response Medical continues to make progress with the Welch Allyn range ofproducts, despite short-term supply problems from the USA. In the near future weexpect to negotiate a number of new distribution contracts as we broaden thedivision's product portfolio with innovative monitoring devices. Aged Care Division EMS Medical continues to trade in line with expectations. EMS Medicaldistributes our branded washable and disposable continence care products fromMartex, Kylie and Kanga, which are competing strongly in the NHS home deliverymarket. A new exclusive distribution contract covering the UK, Scandinavia andthe Middle East was concluded for the supply of Inogen One, a lightweight,portable oxygen concentrator, equipped with features that no competitor canmatch at present. We believe that this product has the potential to addsubstantial growth to the division's sales revenues and profits over the nexttwo years. Safe Needle Progress During the period IMD obtained a CE Marketing certificate for the safe needleproduct, "Clip-On". IMD is currently in the process of identifying potentialdistributors in the main target markets where we own the patents in France,Spain, Italy, Sweden, Holland, Canada and the USA. We have appointed a medicaldevice design and engineering consultancy to work alongside IMD in order toassist the market development process. Parallel to this market developmentprocess, an evaluation process is in progress for the sourcing of the productfrom OEM needle manufacturers. Further design enhancements are being made to theproduct following feedback from the NHS and other potential users, includingoverseas clinicians and vets. IMD will commence a trial production batch of20,000 needles by the end of June, with a lead into a first production of 5million needles by September, with a sales launch planned for key markets in thesame month. The process of bringing the safe needle to the market started inearnest following the acquisition of Response Medical last April. We are pleasedto have obtained the CE Marking and have the current launch plan within thistimeframe. Integration The challenge for IMD is to fully integrate the five businesses that have beenbought to date. Matthew Root, a director of Response Medical, has now beenappointed Group Commercial Director. His role is to focus on all new businessdevelopment opportunities, optimising sales of IMD's product portfolios acrossthe four divisions. He is also responsible for the exploitation of our safeneedle technology IP. Functions including accounting, treasury and HR have beencentralised, whilst logistics and warehousing are now located on only threesites in Gloucester, Chipping Campden and Selby. Dividend Policy In the financial review of our Annual Report we stated that in the future theCompany hoped to adopt a progressive dividend policy. I am pleased to informshareholders that it is now the Company's intention to commence making dividendpayments in the next financial year to 31st August 2008. Conclusion IMD remains on track to deliver what it set out to do. Our 'build and buy'strategy is delivering a profitable, medical device distribution business. Fundsraised have been used to finance acquisitions that expand our product portfolioand establish channels to market in the UK and overseas. We can now begin toexploit these channels by commercialising the safe needle technology acquired in2005. The success of our business strategy to date is reflected in this interimreport, where IMD has delivered a significant operating profit of £416,000 on 6month's revenues of £5,063,000. The Group will continue to focus on deliveringorganic growth from the current businesses, whilst continuing to identify newgrowth opportunities via acquisitions and by securing new distribution contractsthat add to our product portfolio. The company expects continued improvement in operating performance in the secondhalf, as the contribution from recent acquisitions increases, although this willbe largely offset by higher interest costs. On behalf of the Board I would like to thank all staff and the executive teamfor their hard work over the past six months. L.C.S Sanford Chairman 26 March 2007 CONSOLIDATED INCOME STATEMENT SIX MONTHS ENDED 28 FEBRUARY 2007 Unaudited Unaudited Audited 6 months to 6 months to Year to 28-Feb-07 28-Feb-06 31-Aug-06 £'000 £'000 £'000 Revenue 5,063 779 3,817Cost of sales (3,121) (515) (2,443) Gross profit 1,942 264 1,374 Distribution expenses (647) - (460)Administration expenses (879) (423) (1,136) Operating Profit/(Loss) before 416 (159) (222)exceptional items Restructure costs - - (85) Operating Profit/(Loss) 416 (159) (307) Finance costs (122) - (70) Finance income 8 1 17 Profit/(Loss) before tax 302 (158) (360)Taxation - - - Profit/(Loss) for the period 302 (158) (360) Earnings per shareBasic £0.0012 £(0.0125) £(0.0021)Diluted £0.0011 - - STATEMENTS OF CHANGES IN EQUITY SIX MONTHS ENDED 28 FEBRUARY 2007 Share Share Capital Retained Total Capital Premium Reserve Earnings £'000 £'000 £ '000 £'000 £'000Balance as at 1 September 2005 1,245 7,251 - (316) 8,180 Changes in equity for the Six months to28 February 2006:Loss for the period - - - (158) (158) Total recognised income and expense for - - - (158) (158)the PeriodIssue of share capital 20 180 - - 200 Movement in Period 20 180 0 (158) 42 Unaudited Balance as at 28 February 2006 1,265 7,431 - (474) 8,222 Changes in equity for the Six months to31 August 2006:Loss for the period - - - (203) (203) Total recognised income and expense for - - - (203) (203)the PeriodIssue of share capital 1,224 5,601 - - 6,825Issue Costs - (533) - - (533) Deferred contingent consideration - - 1,350 - 1,350 Movement in Period 1,224 5,068 1,350 (203) 7,439 Balance as at 31 August 2006 2,489 12,499 1,350 (677) 15,661 Changes in equity for the Six months to28 February 2007:Profit for the period - - - 302 302 Total recognised income and expense for - - - 302 302the PeriodIssue of share capital 199 1,161 - - 1,360 Deferred contingent consideration - - 1,240 - 1,240 Movement in Period 199 1,161 1,240 302 2,902 Unaudited Balance as at 28 February 2007 2,688 13,660 2,590 (375) 18,563 BALANCE SHEET SIX MONTHS ENDED 28 FEBRUARY 2007 Unaudited Unaudited Audited 6 months to 6 months to Year to 28-Feb-07 28-Feb-06 31-Aug-06 £'000 £'000 £'000AssetsNon-current assetsGoodwill 13,683 280 8,674Other Intangible Assets 8,694 7,952 8,479Property, plant and equipment 257 100 233 22,634 8,332 17,386Current AssetsInventories 2,249 212 1,719Trade receivables 2,433 500 1,276Other receivables 316 - 290Cash and cash equivalents 629 77 706 5,627 789 3,991 Total assets 28,261 9,121 21,377 Equity and liabilitiesEquity attributable to equity holders of theparentShare capital 2,688 1,265 2,489Share premium 13,660 7,430 12,499Capital reserves 2,590 - 1,350Retained earnings (375) (474) (677) 18,563 8,221 15,661Non-current liabilitiesBank loans 2,955 - 1,300Convertible loan notes 250 - 250Other non-current liabilities 388 - 444 3,593 - 1,994Current liabilitiesTrade and other payables 4,855 900 3,122Convertible loan notes 250 - 250Bank loans 1,000 - 350 6,105 900 3,722 Total liabilities 9,698 900 5,716 Total equity and liabilities 28,261 9,121 21,377 CONSOLIDATED CASH FLOW STATEMENT SIX MONTHS ENDED 28 FEBRUARY 2007 Unaudited Unaudited Audited 6 months to 6 months to Year to 28-Feb-07 28-Feb-06 31-Aug-06 £'000 £'000 £'000Cash flows from operating activitiesProfit/(Loss) from operations 416 (159) (307) Adjustments for:Depreciation of property, plant and equipment 47 5 45Charge in relation to Share Options 9 - - Operating cash flows before movement in working capital 472 (154) (262) (Increase) in inventories (59) (212) (316)(Increase)/Decrease in receivables (409) (372) 892(Decrease) in payables (275) 635 (320)Tax paid (132) - (80) Cash generated from operations (403) (103) (86) Interest paid (56) - (70) Net cash from/(used in) operating activities (459) (103) (156) Cash flows from investing activitiesInterest received 8 1 17Acquisition of Non Current Assets (308) - (44)Acquisition of Subsidiary net of cash acquired (2,493) (384) (2,434) Net cash (used in) investment activities (2,793) (383) (2,461) Cash flows from financing activitiesNet proceeds on issues of shares - 200 2,815Net borrowings 3,175 - 145 Net cash from financing activities 3,175 200 2,960 Net decrease in cash and cash equivalents (77) (286) 343 Cash and cash equivalents at beginning of period 706 363 363 Cash and cash equivalents at end of period 629 77 706 Bank balances and cash 629 77 706 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS SIX MONTHS ENDED 28 FEBRUARY 2007 1. Presentation of Financial Statements The financial information contained in this Interim Statement for the 6 monthsended 28 February 2007 is unaudited and does not comprise accounts within themeaning of s240 of the Companies Act 1985. The financial information for thefull preceding period is based on the statutory Report and Accounts for thefinancial year ended 31 August 2006 which were reported on by the auditors,without qualification or statement under Section 237 (2) or (3) of the CompaniesAct 1985 and have been delivered to the Registrar of Companies. The financial information has been prepared in accordance with InternationalAccounting Standard 34 "Interim Financial Reporting". The interim financial information has been prepared on the basis of accountingpolicies set out in the group's statutory accounts for the year ended 31 August2006. The interim accounts should be read in conjunction with the Group'saudited accounts for the year ended 31 August 2006. The Consolidated financial statements include the financial statements of theCompany and its subsidiaries to 28 February 2007. Assets and liabilities thatexist at the date of acquisition are recorded at their fair values reflectingtheir condition at that date. Purchased goodwill arising on consolidationrepresents the excess of the fair value of the consideration given, plusassociated costs, for a business over the fair value of the assets acquired.Goodwill arising on acquisition is capitalised as an intangible fixed asset. 2. Acquisitions Pro-Care Limited and Minster Medical Limited were acquired on 22 December 2006,and the Consolidated Financial Statements therefore include revenue and costsrelating to these acquisitions from that date to 28 February 2007. Pro-Care Limited and Minster Medical Limited acquisitionsconsideration included the issue of 17,857,142 shares to the vendors at a priceof 7 pence per share, with a nominal value of 1 pence per share, the balancebeing attributed to the share premium account. 3. Taxation No tax charge has been incorporated into the consolidated accountsfor the period ended 28 February 2007, due to availability of tax losses withinthe group to offset taxable profits. 4. Earnings per Share The Earnings per Ordinary Share in this interim period is calculated byreference to the Profit after Tax of £302,000 and the weighted average number of256,505,629 shares in issue (fully diluted 282,544,303) during this period. Theperiod ended 28 February 2006 the Company incurred a loss of £(158,000) and theweighted average number of shares was 126,160,000. For the year to 31 August2006, a loss of £(360,000) was incurred and the weighted average number ofshares amounted to 171,314,367. 5. Copies of Accounts A copy of this half-year report will be distributed to all shareholders and willalso be available to members of the public from the Company's registered officeaddress at 10 Orange Street, London, WC2H 7DQ. A copy of the interim reportwill also be available on the Company's website www.imd-plc.com This information is provided by RNS The company news service from the London Stock Exchange

Related Shares:

Intelliam Ai
FTSE 100 Latest
Value10,416.68
Change-36.00